Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas Easley, SC
354
mi
from 43215
Easley, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas Easley, SC
354
mi
from 43215
Easley, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
St. Francis Hospital
496
mi
from 43215
Roslyn, NY
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
St. Francis Hospital
496
mi
from 43215
Roslyn, NY
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas - Eastside
354
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Eastside
354
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas - Faris Road
357
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
357
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Greenville Hospital System Univeristy Medical Center
358
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Greenville Hospital System Univeristy Medical Center
358
mi
from 43215
Greenville, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Self Regional Cancer Center at Self Regional Medical Center
403
mi
from 43215
Greenwood, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Self Regional Cancer Center at Self Regional Medical Center
403
mi
from 43215
Greenwood, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas - Greer Medical Oncology
351
mi
from 43215
Greer, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Greer Medical Oncology
351
mi
from 43215
Greer, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas - Seneca
364
mi
from 43215
Seneca, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Seneca
364
mi
from 43215
Seneca, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Centers of the Carolinas - Spartanburg
349
mi
from 43215
Spartanburg, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Spartanburg
349
mi
from 43215
Spartanburg, SC
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Medical X-Ray Center, PC
747
mi
from 43215
Sioux Falls, SD
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Medical X-Ray Center, PC
747
mi
from 43215
Sioux Falls, SD
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Sanford USD Medical Center
752
mi
from 43215
Sioux Falls, SD
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Sanford USD Medical Center
752
mi
from 43215
Sioux Falls, SD
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
University of Texas - Southwest
911
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Texas - Southwest
911
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Parkland Health & Hospital Systems
911
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Parkland Health & Hospital Systems
911
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
910
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
910
mi
from 43215
Dallas, TX
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
St. Joseph's Hospital
163
mi
from 43215
Ann Arbor, MI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
St. Joseph's Hospital
163
mi
from 43215
Ann Arbor, MI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Olympic Hematology and Oncology
2020
mi
from 43215
Bremerton, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Olympic Hematology and Oncology
2020
mi
from 43215
Bremerton, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Kadlec Hematology & Oncology
1856
mi
from 43215
Kennewick, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Kadlec Hematology & Oncology
1856
mi
from 43215
Kennewick, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Harrison Poulsbo Hematology and Onocology
2021
mi
from 43215
Poulsbo, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Harrison Poulsbo Hematology and Onocology
2021
mi
from 43215
Poulsbo, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
University of Washington; UW Medical Center
1982
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
1982
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
University Cancer Center at University of Washington Medical Center
1982
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University Cancer Center at University of Washington Medical Center
1982
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Minor and James Medical, PLLC
2006
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Minor and James Medical, PLLC
2006
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Group Health Capitol Hill Campus
2006
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Group Health Capitol Hill Campus
2006
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Polyclinic First Hill
2005
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Polyclinic First Hill
2005
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Swedish Cancer Center
2005
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Swedish Cancer Center
2005
mi
from 43215
Seattle, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Cancer Care Northwest - Spokane South
1777
mi
from 43215
Spokane, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
1777
mi
from 43215
Spokane, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Evergreen Hematology & Oncology
1778
mi
from 43215
Spokane, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Evergreen Hematology & Oncology
1778
mi
from 43215
Spokane, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Madigan Army Medical Center
2017
mi
from 43215
Fort Lewis-DuPont, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Madigan Army Medical Center
2017
mi
from 43215
Fort Lewis-DuPont, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Wenatchee Valley Medical Center
1912
mi
from 43215
Wenatchee, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
1912
mi
from 43215
Wenatchee, WA
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Columbia Saint Mary's Hospital - Ozaukee
342
mi
from 43215
Mequon, WI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Columbia Saint Mary's Hospital - Ozaukee
342
mi
from 43215
Mequon, WI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Columbia-Saint Mary's Cancer Care Center
331
mi
from 43215
Milwaukee, WI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Columbia-Saint Mary's Cancer Care Center
331
mi
from 43215
Milwaukee, WI
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Rocky Mountain Oncology
1217
mi
from 43215
Casper, WY
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
1217
mi
from 43215
Casper, WY
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
Breast Duct Lavage, Breast Duct Endoscopy, and Gene Expression Profiling in Women With Breast Cancer or Healthy Women Who Are and Are Not at High Risk for Breast Cancer
Characterization Of High Risk Breast Duct Epithelium By Cytology, Breast Duct Endoscopy, And cDNA Gene Expression Profile
Status: Archived
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Breast Duct Lavage, Breast Duct Endoscopy, and Gene Expression Profiling in Women With Breast Cancer or Healthy Women Who Are and Are Not at High Risk for Breast Cancer
Characterization Of High Risk Breast Duct Epithelium By Cytology, Breast Duct Endoscopy, And cDNA Gene Expression Profile
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Inflammatory Breast Cancer and Tumor Markers
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Inflammatory Breast Cancer and Tumor Markers
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Glendale Memorial Hospital
1970
mi
from 43215
Glendale, CA
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Updated: 1/1/1970
Glendale Memorial Hospital
1970
mi
from 43215
Glendale, CA
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Hollywood Presbyterian Medical Center
1973
mi
from 43215
Los Angeles, CA
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
Status: Archived
Updated: 1/1/1970
Hollywood Presbyterian Medical Center
1973
mi
from 43215
Los Angeles, CA
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer
Status: Archived
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities
Improving the Delivery of Effective Care to Minorities
Status: Archived
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities
Improving the Delivery of Effective Care to Minorities
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer
Status: Archived
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
A Phase II Trial of Exemestane (Aromasin) in Combination With Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Status: Archived
Ohio State University
2
mi
from 43215
Columbus, OH
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
A Phase II Trial of Exemestane (Aromasin) in Combination With Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Status: Archived
Updated: 1/1/1970
Ohio State University
2
mi
from 43215
Columbus, OH
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Columbia Presbyterian Med Ctr
481
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
481
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Albert Einstein College of Medicine
486
mi
from 43215
Bronx, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Harlem Hospital, Columbia University
481
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Harlem Hospital, Columbia University
481
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Metropolitan Hosp. NICHD CRS
480
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Metropolitan Hosp. NICHD CRS
480
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
North General Hospital
477
mi
from 43215
New York, NY
Patient Centered Randomized Controlled Trial
Patient Assistance to Reduce Breast Cancer Disparities
Status: Archived
Updated: 1/1/1970
North General Hospital
477
mi
from 43215
New York, NY